Gaprin Market Volume 2023-2030

Gaprin Market Volume 2023-2030

Oct 31, 2023

The global Gaprin market was valued at US$ 48.43 million in 2022 and is anticipated to reach US$ 589.55 million by 2029, witnessing a CAGR of 42.70% during the forecast period 2023-2029. The influence of COVID-19 and the Netherlands-Ukraine War were considered while estimating market sizes.

Gaprin is a complete microbiological protein derived from inactivated cells of non-pathogenic methanotrophic bacteria. It serves as a valuable biomass containing high-quality protein without the presence of antibiotics or hormones. Moreover, Gaprin offers a rich source of amino acids, vitamins, and minerals.
Report Sample includes:

  • Table of Contents
  • List of Tables & Figures
  • Charts
  • Research Methodology

Get FREE Sample of this Report at

The food and beverage industry represents a significant consumer base for Gaprin. It finds application in a diverse range of food products, including meat alternatives, dairy items, and beverages. The increasing demand within the food and beverage sector for sustainable protein sources of exceptional quality has become a key driving factor for the expanding Gaprin market in this particular segment.

Furthermore, the animal feed industry constitutes another major sector where Gaprin finds utility. It is utilized as a protein supplement within animal feed formulations. The rising demand for animal feed in developing nations plays a crucial role in propelling the growth of the Gaprin market within this specific segment.

The major global manufacturers of Gaprin include: Unibio, Calysta, Prtotelux, Metanica, Giprobiosyntez, and etc. In 2022, the world's top three vendors accounted for approximately 61.37 % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Gaprin, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gaprin.

The Gaprin market size, estimations, and forecasts are provided in terms of sales volume (K Tons) and revenue ($ millions), considering 2021 as the base year, with history and forecast data for the period from 2017 to 2028. This report segments the global Gaprin market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Gaprin manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

By Company

  • Unibio
  • Calysta
  • Prtotelux
  • Metanica
  • Giprobiosyntez

Segment by Type

  • Food Grade Gaprin
  • Feed Grade Gaprin

Segment by Application

  • Food & Beverages
  • Animal Feed
  • Others

North American market for Gaprin is estimated to increase from $ 11.68 million in 2023 to reach $ 88.84 million by 2029, at a CAGR of 40.24 % during the forecast period of 2023 through 2029.

Asia-Pacific market for Gaprin is estimated to increase from $ 34.31 million in 2023 to reach $ 317.35 million by 2029, at a CAGR of 44.88 % during the forecast period of 2023 through 2029.

Consumption by Region

  • North America
  • U.S.
  • Canada

  • Asia-Pacific
  • China
  • Japan
  • South Korea
  • China Taiwan
  • Southeast Asia
  • India

  • Europe
  • Germany
  • France
  • U.K.
  • Italy
  • CIS
  • Rest of Europe

  • South America
  • Mexico
  • Brazil
  • Rest of South America

Recent Developments:

  • In February 2023, Unibio announced that it had received regulatory approval for the sale of Gaprin in the European Union. This is a significant milestone for Unibio, as it opens up the European market for Gaprin.
  • In March 2023, Calysta announced that it had received funding from the Bill & Melinda Gates Foundation to support the development of Gaprin as a protein source for animal feed. This funding will help Calysta to accelerate the commercialization of Gaprin for animal feed.
  • In April 2023, Prtotelux announced that it had entered into a partnership with Cargill to develop and commercialize Gaprin. This partnership will bring together Prtotelux's technology for producing Gaprin and Cargill's global reach to the food and feed industry.

Market Drivers:

Growing Demand for Sustainable Protein Sources: There is an increasing global demand for sustainable and environmentally friendly protein sources. Gaprin, being derived from non-pathogenic methanotrophic bacteria, offers a viable solution as a renewable protein source.
Rising Awareness of Health and Nutrition: Consumers are becoming more health-conscious and seeking nutritious food products. Gaprin, being a high-quality protein source, free of antibiotics and hormones, aligns with the growing demand for healthier and cleaner food options.
Expansion of the Food and Beverage Industry: The food and beverage industry continues to experience growth, driven by changing consumer preferences and dietary patterns. Gaprin finds applications in various food products, including meat substitutes, dairy products, and beverages, catering to the evolving needs of consumers.
Increasing Demand in Animal Feed: The animal feed industry is witnessing growth due to the rising demand for livestock products. Gaprin serves as a protein supplement in animal feed, meeting the protein requirements of animals in a sustainable manner.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the Gaprin market analysis from 2022 to 2032 to identify the prevailing Gaprin market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the Gaprin market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional Gaprin market trends, key players, market segments, application areas, and market growth strategies.

Market Restraints:

Limited Awareness and Acceptance: Gaprin is a relatively new protein source in the market, and its adoption may be hindered by limited awareness and acceptance among consumers and manufacturers. Educating and creating awareness about the benefits and safety of Gaprin will be crucial in overcoming this restraint.
Regulatory Challenges: The introduction of any novel ingredient or protein source into the market may face regulatory hurdles and compliance requirements. Ensuring compliance with regulatory standards and obtaining necessary approvals can be a challenge for the Gaprin market.
Competitive Landscape: The market for alternative protein sources is becoming increasingly competitive, with numerous players and options available. Gaprin will need to differentiate itself and demonstrate its unique advantages to gain market share in this competitive landscape.
Cost Considerations: The production and commercialization of Gaprin may face cost challenges, especially in comparison to traditional protein sources. Achieving cost competitiveness while maintaining quality standards will be crucial for market success.

Get the Complete Report & TOC at


276 5th Avenue, New York , NY 10001,United States
International: (+1) 646 781 7170

Email: [email protected]

Follow Us On linkedin :-